Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 538141, 7 pages
http://dx.doi.org/10.1155/2008/538141
Review Article

Peroxisome Proliferator-Activated Receptors: “Key” Regulators of Neuroinflammation after Traumatic Brain Injury

1Department of Orthopedic Surgery, Denver Health Medical Center, School of Medicine, University of Colorado, 777 Bannock Street, Denver, CO 80204, USA
2Division of Neurosurgery, Department of Surgery , Denver Health Medical Center, School of Medicine, University of Colorado, 777 Bannock Street, Denver, CO 80204, USA

Received 24 December 2007; Accepted 29 January 2008

Academic Editor: Paul Drew

Copyright © 2008 Philip F. Stahel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. M. McMillan and G. M. Teasdale, “Death rate is increased for at least 7 years after head injury: a prospective study,” Brain, vol. 130, no. 10, pp. 2520–2527, 2007. View at Publisher · View at Google Scholar
  2. J. F. Holmes, G. W. Hendey, J. A. Oman et al., “Epidemiology of blunt head injury victims undergoing ED cranial computed tomographic scanning,” American Journal of Emergency Medicine, vol. 24, no. 2, pp. 167–173, 2006. View at Publisher · View at Google Scholar
  3. E. M. R. Doppenberg, S. C. Choi, and R. Bullock, “Clinical trials in traumatic brain injury: lessons for the future,” Journal of Neurosurgical Anesthesiology, vol. 16, no. 1, pp. 87–94, 2004. View at Publisher · View at Google Scholar
  4. R. M. Chesnut, “Care of central nervous system injuries,” Surgical Clinics of North America, vol. 87, no. 1, pp. 119–156, 2007. View at Publisher · View at Google Scholar
  5. H. Bayir, P. M. Kochanek, and R. S. B. Clark, “Traumatic brain injury in infants and children mechanisms of secondary damage and treatment in the intensive care unit,” Critical Care Clinics, vol. 19, no. 3, pp. 529–549, 2003. View at Publisher · View at Google Scholar
  6. H. G. Fritz and R. Bauer, “Secondary injuries in brain trauma: effects of hypothermia,” Journal of Neurosurgical Anesthesiology, vol. 16, no. 1, pp. 43–52, 2004. View at Publisher · View at Google Scholar
  7. P. M. Kochanek, R. S. B. Clark, R. A. Ruppel et al., “Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: lessons learned from the bedside,” Pediatric Critical Care Medicine, vol. 1, no. 1, pp. 4–19, 2000. View at Publisher · View at Google Scholar
  8. O. I. Schmidt, C. E. Heyde, W. Ertel, and P. F. Stahel, “Closed head injury: an inflammatory disease?” Brain Research Reviews, vol. 48, no. 2, pp. 388–399, 2005. View at Publisher · View at Google Scholar
  9. P. F. Stahel, W. R. Smith, and E. E. Moore, “Role of biological modifiers regulating the immune response after trauma,” Injury, vol. 38, no. 12, pp. 1409–1422, 2007. View at Publisher · View at Google Scholar
  10. B. J. Kelley, J. Lifshitz, and J. T. Povlishock, “Neuroinflammatory responses after experimental diffuse traumatic brain injury,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 11, pp. 989–1001, 2007. View at Publisher · View at Google Scholar
  11. P. F. Stahel, W. R. Smith, and E. E. Moore, “Hypoxia and hypotension, the “lethal duo” in traumatic brain injury: implications for prehospital care,” Intensive Care Medicine, vol. 34, no. 3, pp. 402–404, 2008. View at Publisher · View at Google Scholar
  12. B. J. Eastridge, J. Salinas, J. G. McManus et al., “Hypotension begins at 110 mm Hg: redefining “hypotension” with data,” Journal of Trauma-Injury Infection & Critical Care, vol. 63, no. 2, pp. 291–297, 2007, discussion 297–299. View at Publisher · View at Google Scholar
  13. R. R. Leker and E. Shohami, “Cerebral ischemia and trauma—different etiologies yet similar mechanisms: neuroprotective opportunities,” Brain Research Reviews, vol. 39, no. 1, pp. 55–73, 2002. View at Publisher · View at Google Scholar
  14. R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1341–1346, 2006. View at Publisher · View at Google Scholar
  15. S. van Neerven and J. Mey, “RAR/RXR and PPAR/RXR signaling in spinal cord injury,” PPAR Research, vol. 2007, Article ID 29275, 14 pages, 2007. View at Publisher · View at Google Scholar
  16. T. Genovese, E. Mazzon, R. Di Paola et al., “Role of endogenous ligands for the peroxisome proliferators activated receptors a in the secondary damage in experimental spinal cord trauma,” Experimental Neurology, vol. 194, no. 1, pp. 267–278, 2005. View at Publisher · View at Google Scholar
  17. X. R. Chen, V. C. Besson, B. Palmier, Y. Garcia, M. Plotkine, and C. Marchand-Leroux, “Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR α agonist, in traumatic brain injury,” Journal of Neurotrauma, vol. 24, no. 7, pp. 1119–1131, 2007. View at Publisher · View at Google Scholar
  18. M. Allahtavakoli, A. Shabanzadeh, A. Roohbakhsh, and A. Pourshanazari, “Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-γ ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats,” Basic & Clinical Pharmacology & Toxicology, vol. 101, no. 5, pp. 309–314, 2007. View at Publisher · View at Google Scholar
  19. X. Zhao, G. Sun, J. Zhang et al., “Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor ? in microglia/macrophages,” Annals of Neurology, vol. 61, no. 4, pp. 352–362, 2007. View at Publisher · View at Google Scholar
  20. R. Kapadia, J.-H. Yi, and R. Vemuganti, “Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-γ agonists,” Frontiers in Bioscience, vol. 13, pp. 1813–1826, 2008. View at Publisher · View at Google Scholar
  21. V. C. Besson, X. R. Chen, M. Plotkine, and C. Marchand-Verrecchia, “Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury,” Neuroscience Letters, vol. 388, no. 1, pp. 7–12, 2005. View at Publisher · View at Google Scholar
  22. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
  23. L. Michalik and W. Wahli, “Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions,” Current Opinion in Biotechnology, vol. 10, no. 6, pp. 564–570, 1999. View at Publisher · View at Google Scholar
  24. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–263, 2001. View at Publisher · View at Google Scholar
  25. K. Schoonjans, J. Peinado-Onsurbe, A. M. Lefebvre et al., “PPARa and PPAR? activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996. View at Google Scholar
  26. B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005. View at Publisher · View at Google Scholar
  27. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995. View at Publisher · View at Google Scholar
  28. R. P. Brun, P. Tontonoz, B. M. Forman et al., “Differential activation of adipogenesis by multiple PPAR isoforms,” Genes and Development, vol. 10, no. 8, pp. 974–984, 1996. View at Publisher · View at Google Scholar
  29. N. S. Tan, L. Michalik, N. Noy et al., “Critical roles of PPAR ß/d in keratinocyte response to inflammation,” Genes & Development, vol. 15, no. 24, pp. 3263–3277, 2001. View at Publisher · View at Google Scholar
  30. S. Kersten, “Peroxisome proliferator activated receptors and lipoprotein metabolism,” PPAR Research, vol. 2008, Article ID 132960, 11 pages, 2008. View at Publisher · View at Google Scholar
  31. G. Martinasso, M. Oraldi, A. Trombetta et al., “Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines,” PPAR Research, vol. 2007, Article ID 93416, 9 pages, 2007. View at Publisher · View at Google Scholar
  32. B. Lecka-Czernik, “PPARs and bone metabolism,” PPAR Research, vol. 2006, Article ID 18089, p. 1 page, 2006. View at Publisher · View at Google Scholar
  33. S. Z. Duan, C. Y. Ivashchenko, M. G. Usher, and R. M. Mortensen, “PPAR-γ in the cardiovascular system,” PPAR Research, vol. 2008, Article ID 745804, 10 pages, 2008. View at Google Scholar
  34. R. Di Paola and S. Cuzzocrea, “Peroxisome proliferator-activated receptors and acute lung injury,” PPAR Research, vol. 2007, Article ID 63745, 8 pages, 2007. View at Publisher · View at Google Scholar
  35. T. H.-W. Huang, V. Razmovski-Naumovski, B. P. Kota, D. S.-H. Lin, and B. D. Roufogalis, “The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases,” Respiratory Research, vol. 6, Article ID 102, 9 pages, 2005. View at Publisher · View at Google Scholar
  36. P. Delerive, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001. View at Publisher · View at Google Scholar
  37. A. Cabrero, J. C. Laguna, and M. Vazquez, “Peroxisome proliferator-activated receptors and the control of inflammation,” Current Drug Targets—Inflammation & Allergy, vol. 1, no. 3, pp. 243–248, 2002. View at Publisher · View at Google Scholar
  38. G. Chinetti, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000. View at Publisher · View at Google Scholar
  39. R. S. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002. View at Google Scholar
  40. R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002. View at Publisher · View at Google Scholar
  41. R. S. B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S. J. Padula, “The nuclear receptor PPAR γ and immunoregulation: PPAR γ mediates inhibition of helper T cell responses,” Journal of Immunology, vol. 164, no. 3, pp. 1364–1371, 2000. View at Google Scholar
  42. D. M. Ray, F. Akbiyik, S. H. Bernstein, and R. P. Phipps, “CD40 engagement prevents peroxisome proliferator-activated receptor γ agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-κB-dependent mechanism,” Journal of Immunology, vol. 174, pp. 4060–4069, 2005. View at Google Scholar
  43. B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar
  44. M. E. Poynter and R. A. Daynes, “Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32833–32841, 1998. View at Publisher · View at Google Scholar
  45. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  46. L. Michalik and W. Wahli, “Involvement of PPAR nuclear receptors in tissue injury and wound repair,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 598–606, 2006. View at Publisher · View at Google Scholar
  47. S. Cuzzocrea, E. Mazzon, R. Di Paola et al., “The role of the peroxisome proliferator-activated receptor-a (PPAR-a) in the regulation of acute inflammation,” Journal of Leukocyte Biology, vol. 79, no. 5, pp. 999–1010, 2006. View at Publisher · View at Google Scholar
  48. T. E. Cullingford, K. Bhakoo, S. Peuchen, C. T. Dolphin, R. Patel, and J. B. Clark, “Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system,” Journal of Neurochemistry, vol. 70, no. 4, pp. 1366–1375, 1998. View at Google Scholar
  49. S. Moreno, S. Farioli-Vecchioli, and M. P. Cerù, “Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS,” Neuroscience, vol. 123, no. 1, pp. 131–145, 2004. View at Publisher · View at Google Scholar
  50. M. Collino, M. Aragno, R. Mastrocola et al., “Modulation of the oxidative stress and inflammatory response by PPAR-? agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion,” European Journal of Pharmacology, vol. 530, no. 1-2, pp. 70–80, 2006. View at Publisher · View at Google Scholar
  51. S.-D. Chen, H.-Y. Wu, D.-I. Yang et al., “Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2,” Biochemical and Biophysical Research Communications, vol. 351, no. 1, pp. 198–203, 2006. View at Publisher · View at Google Scholar
  52. Y. Luo, W. Yin, A. P. Signore et al., “Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-? agonist rosiglitazone,” Journal of Neurochemistry, vol. 97, no. 2, pp. 435–448, 2006. View at Publisher · View at Google Scholar
  53. E. Shohami, M. Novikov, R. Bass, A. Yamin, and R. Gallily, “Closed head injury triggers early production of TNF-α and IL-6 by brain tissue,” Journal of Cerebral Blood Flow & Metabolism, vol. 14, pp. 615–619, 1994. View at Google Scholar
  54. L. Fan, P. R. Young, F. C. Barone, G. Z. Feuerstein, D. H. Smith, and T. K. McIntosh, “Experimental brain injury induces differential expression of tumor necrosis factor-α mRNA in the CNS,” Molecular Brain Research, vol. 36, no. 2, pp. 287–291, 1996. View at Publisher · View at Google Scholar
  55. S. M. Knoblach, L. Fan, and A. I. Faden, “Early neuronal expression of tumor necrosis factor-α after experimental brain injury contributes to neurological impairment,” Journal of Neuroimmunology, vol. 95, no. 1-2, pp. 115–125, 1999. View at Publisher · View at Google Scholar
  56. E. Shohami, R. Bass, D. Wallach, A. Yamin, and R. Gallily, “Inhibition of tumor necrosis factor α (TNFα) activity in rat brain is associated with cerebroprotection after closed head injury,” Journal of Cerebral Blood Flow & Metabolism, vol. 16, pp. 378–384, 1996. View at Publisher · View at Google Scholar
  57. E. Shohami, I. Ginis, and J. M. Hallenbeck, “Dual role of tumor necrosis factor α in brain injury,” Cytokine and Growth Factor Reviews, vol. 10, no. 2, pp. 119–130, 1999. View at Publisher · View at Google Scholar
  58. A. Gopcevic, B. Mazul-Sunko, J. Marout et al., “Plasma interleukin-8 as a potential predictor of mortality in adult patients with severe traumatic brain injury,” Tohoku Journal of Experimental Medicine, vol. 211, no. 4, pp. 387–393, 2007. View at Publisher · View at Google Scholar
  59. P. F. Stahel, T. Kossmann, H. Joller, O. Trentz, and M. C. Morganti-Kossmann, “Increased interleukin-12 levels in human cerebrospinal fluid following severe head trauma,” Neuroscience Letters, vol. 249, no. 2-3, pp. 123–126, 1998. View at Publisher · View at Google Scholar
  60. U. Felderhoff-Mueser, O. I. Schmidt, A. Oberholzer, C. Buhrer, and P. F. Stahel, “IL-18: a key player in neuroinflammation and neurodegeneration?” Trends in Neurosciences, vol. 28, no. 9, pp. 487–493, 2005. View at Publisher · View at Google Scholar
  61. S.-M. Lucas, N. J. Rothwell, and R. M. Gibson, “The role of inflammation in CNS injury and disease,” British Journal of Pharmacology, vol. 147, supplement 1, pp. S232–S240, 2006. View at Publisher · View at Google Scholar
  62. R. Bordet, P. Gelé, P. Duriez, and J.-C. Fruchart, “PPARs: a new target for neuroprotection,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 3, pp. 285–286, 2006. View at Publisher · View at Google Scholar
  63. A. Bernando and L. Minghetti, “PPAR-γ agonists as regulators of microglial activation and brain inflammation,” Current Pharmaceutical Design, vol. 12, no. 1, pp. 93–109, 2006. View at Publisher · View at Google Scholar
  64. M. Niino, K. Iwabuchi, S. Kikuchi et al., “Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-?,” Journal of Neuroimmunology, vol. 116, no. 1, pp. 40–48, 2001. View at Publisher · View at Google Scholar
  65. C. Natarajan and J. J. Bright, “Peroxisome proliferator-activated receptor-γ agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation,” Genes & Immunity, vol. 3, no. 2, pp. 59–70, 2002. View at Publisher · View at Google Scholar
  66. H. A. Pershadsingh, M. T. Heneka, R. Saini, N. M. Amin, D. J. Broeske, and D. L. Feinstein, “Effect of pioglitazone treatment in a patient with secondary multiple sclerosis,” Journal of Neuroinflammation, vol. 1, article 3, pp. 1–4, 2004. View at Publisher · View at Google Scholar
  67. R. E. Mrak and G. E. Landreth, “PPARγ, neuroinflammation, and disease,” Journal of Neuroinflammation, vol. 1, article 5, pp. 1–3, 2004. View at Publisher · View at Google Scholar
  68. D. Deplanque, P. Gelé, O. Pétrault et al., “Peroxisome proliferator-activated receptor-a activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment,” Journal of Neuroscience, vol. 23, no. 15, pp. 6264–6271, 2003. View at Google Scholar
  69. O. I. Schmidt, M. Infanger, C. E. Heyde, W. Ertel, and P. F. Stahel, “The role of neuroinflammation in traumatic brain injury,” European Journal of Trauma, vol. 30, no. 3, pp. 135–149, 2004. View at Publisher · View at Google Scholar
  70. P. H. Evans, “Free radicals in brain metabolism and pathology,” British Medical Bulletin, vol. 49, no. 3, pp. 577–587, 1993. View at Google Scholar
  71. P. F. Stahel, M. C. Morganti-Kossmann, and T. Kossmann, “The role of the complement system in traumatic brain injury,” Brain Research Reviews, vol. 27, no. 3, pp. 243–256, 1998. View at Publisher · View at Google Scholar
  72. A. L. D'Ambrosio, D. J. Pinsky, and E. S. Connolly, “The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection,” Molecular Medicine, vol. 7, no. 6, pp. 367–382, 2001. View at Google Scholar
  73. L. Cherian, J. C. Goodman, and C. S. Robertson, “Brain nitric oxide changes after controlled cortical impact injury in rats,” Journal of Neurophysiology, vol. 83, no. 4, pp. 2171–2178, 2000. View at Google Scholar
  74. E. D. Hall, N. C. Kupina, and J. S. Althaus, “Peroxynitrite scavengers for the acute treatment of traumatic brain injury,” Annals of the New York Academy of Sciences, vol. 890, no. 1, pp. 462–468, 1999. View at Publisher · View at Google Scholar
  75. R. K. Narayan, M. E. Michel, B. Ansell et al., “Clinical trials in head injury,” Journal of Neurotrauma, vol. 19, no. 5, pp. 503–557, 2002. View at Publisher · View at Google Scholar
  76. T. J. DeGraba and L. C. Pettigrew, “Why do neuroprotective drugs work in animals but not humans?” Neurologic Clinics, vol. 18, no. 2, pp. 475–493, 2000. View at Publisher · View at Google Scholar
  77. E. Shohami, R. Gallily, R. Mechoulam, R. Bass, and T. Ben-Hur, “Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant,” Journal of Neuroimmunology, vol. 72, no. 2, pp. 169–177, 1997. View at Publisher · View at Google Scholar
  78. R. Mechoulam, D. Panikashvili, and E. Shohami, “Cannabinoids and brain injury: therapeutic implications,” Trends in Molecular Medicine, vol. 8, no. 2, pp. 58–61, 2002. View at Publisher · View at Google Scholar
  79. H. Bayir, R. S. B. Clark, and P. M. Kochanek, “Promising strategies to minimize secondary brain injury after head trauma,” Critical Care Medicine, vol. 31, supplement 1, pp. S112–S117, 2003. View at Publisher · View at Google Scholar
  80. D. Panikashvili, C. Simeonidou, S. Ben-Shabat et al., “An endogenous cannabinoid (2-AG) is neuroprotective after brain injury,” Nature, vol. 413, pp. 527–531, 2001. View at Publisher · View at Google Scholar
  81. R. Mechoulam and E. Shohami, “Endocannabinoids and traumatic brain injury,” Molecular Neurobiology, vol. 36, no. 1, pp. 68–74, 2007. View at Publisher · View at Google Scholar
  82. E. Shohami, M. Novikov, and R. Mechoulam, “A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat,” Journal of Neurotrauma, vol. 10, no. 2, pp. 109–119, 1993. View at Google Scholar
  83. Y. Sun and A. Bennett, “Cannabinoids: a new group of agonists of PPARs,” PPAR Research, vol. 2007, Article ID 23513, 7 pages, 2007. View at Publisher · View at Google Scholar
  84. J. Fu, F. Oveisi, S. Gaetani, E. Lin, and D. Piomelli, “Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats,” Neuropharmacology, vol. 48, no. 8, pp. 1147–1153, 2005. View at Publisher · View at Google Scholar
  85. S. E. O'Sullivan, E. J. Tarling, A. J. Bennett, D. A. Kendall, and M. D. Randall, “Novel time-dependent vascular actions of Δ9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor γ,” Biochemical and Biophysical Research Communications, vol. 337, no. 3, pp. 824–831, 2005. View at Publisher · View at Google Scholar
  86. C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski, “Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2,” Molecular Pharmacology, vol. 70, no. 1, pp. 101–111, 2006. View at Publisher · View at Google Scholar